Suppr超能文献

使用106Ru/106Rh施源器对脉络膜黑色素瘤进行β射线照射。16年经验。

beta-Irradiation of choroidal melanoma with 106Ru/106Rh applicators. 16 Years' experience.

作者信息

Lommatzsch P K

出版信息

Arch Ophthalmol. 1983 May;101(5):713-7. doi: 10.1001/archopht.1983.01040010713002.

Abstract

From 1964 to 1980, 205 patients with choroidal melanoma were treated with 106Ru/106Rh beta-ray applicators (8,000 to 10,000 rad at the summit of the tumor within 14 days). In 132 (64.4%) cases, this treatment was successful. Thirty-six (17.6%) had to be enucleated after irradiation and 37 died, 21 of them of metastases. Of the 132 successfully treated patients, 60 (45.5%) had flat scars and 34 (25.8%) retained a visual acuity of 0.5 to 1.5. Radiogenic late complications with damage to the retinal capillary system were the main causes of visual deterioration, especially in eyes with tumors close to the posterior pole. The survival rate of 85.1% after five years is substantially higher than that for patients who were primarily treated with enucleation.

摘要

1964年至1980年期间,205例脉络膜黑色素瘤患者接受了106钌/106铑β射线敷贴器治疗(在14天内肿瘤顶部接受8000至10000拉德照射)。132例(64.4%)患者治疗成功。36例(17.6%)在照射后不得不摘除眼球,37例死亡,其中21例死于转移。在132例治疗成功的患者中,60例(45.5%)留下扁平瘢痕,34例(25.8%)视力保持在0.5至1.5。视网膜毛细血管系统受损的放射性晚期并发症是视力恶化的主要原因,尤其是肿瘤靠近后极的眼睛。五年后的生存率为85.1%,大大高于主要接受眼球摘除术治疗的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验